Please assess the completion status of the following clinical trial:

Trial Title: A Study of MLN0264 in Patients With Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female participants 18 years of age or older when written informed consent is obtained.~2. Histologically confirmed metastatic or advanced inoperable adenocarcinoma of the pancreas with immunohistochemistry (IHC) evidence of guanylyl cyclase C (GCC) expression indicated by an H-score of 10 or greater.~3. Treatment with 1 or more prior chemotherapies for advanced or metastatic adenocarcinoma of the pancreas.~4. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines. All scans and x-rays used to document measurable disease must be done within 28 days before enrollment (ascites and bone lesions are not considered measureable disease).~5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 14 days before enrollment.~6. Female participants who:~   * Are postmenopausal for at least 1 year before the screening visit, OR~  * Are surgically sterile, OR~  * If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 30 days after the last dose of study drug, or~  * Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence \[eg, calendar, ovulation, symptothermal, postovulation methods\] and withdrawal are not acceptable methods of contraception.)~   Male participants, even if surgically sterilized (ie, status postvasectomy), who:~  * Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or~  * Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence \[eg, calendar, ovulation, symptothermal, postovulation methods for the female partner\] and withdrawal are not acceptable methods of contraception.)~7. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.~8. Adequate organ and hematological function as evidenced by the following laboratory values within 14 days before enrollment:~   * Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L~  * Platelet count ≥ 100 x 10\^9/L~  * Hemoglobin ≥ 9 g/dL~  * Activated partial thromboplastin time (aPTT) ≤ 1.5 x the upper limit of the normal range (ULN) per institutional laboratory normal range~  * International normalized ratio (INR) ≤ 1.5 x ULN~  * Serum creatinine ≤ 1.5 x ULN~  * Total bilirubin ≤ 1.5 x ULN~  * Albumin ≥ 3g/dL~  * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN~  * Serum lipase ≤ 3 x ULN and serum amylase within the normal range~9. Resolution of all toxic effects of prior treatments except alopecia to Grade 0 or 1 by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.~10. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.~Exclusion Criteria:~1. Radiotherapy within 4 weeks before enrollment.~2. Concurrent treatment or treatment within 4 weeks of study entry with any other investigational agent or chemotherapy.~3. Female participants who are lactating and breastfeeding or have a positive pregnancy test during the Screening period.~4. Uncontrolled, clinically significant, symptomatic cardiovascular disease within 6 months before enrollment, including myocardial infarction, unstable angina, Grade 2 or greater peripheral vascular disease, cerebrovascular accident, transient ischemic attack, congestive heart failure, or arrhythmias not controlled by outpatient medication.~5. Treatment with any medication that has a clinically relevant potential risk of prolonging the QT interval or inducing torsades de pointes that cannot be discontinued or switched to a different medication before starting study drug.~6. Participants with electrocardiogram (ECG) abnormalities considered by the investigator to be clinically significant, or repeated baseline prolongation of the rate-corrected QT interval (QTc).~7. Ongoing or clinically significant active infection as judged by the investigator.~8. Signs of peripheral neuropathy (PN) ≥ NCI CTCAE Grade 2.~9. Concomitant chemotherapy, hormonal therapy, immunotherapy, or any other form of cancer treatment.~10. Use of strong cytochrome P450 (CYP) 3A4 inhibitors within 2 weeks before the first dose of study drug.~11. Any preexisting medical condition of sufficient severity to prevent full compliance with the study.~12. History of or current neoplasm other than gastric adenocarcinoma, except for curatively treated nonmelanoma skin cancer or in situ carcinoma of the cervix uteri.~13. Known diagnosis of human immunodeficiency virus (HIV) infection (testing is not mandatory).~14. Symptomatic brain metastases.~15. Ongoing anticoagulant therapy (eg, aspirin, coumadin, heparin).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MLN0264 1.8 mg/kg (Type: EXPERIMENTAL): MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 10 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy